Genotropin (growth hormone pediatric)

Genotropin (growth hormone pediatric) is filed as Growth Hormone. The sections below restate public label fields stored for this profile.

Class
Growth Hormone
Generic name
growth hormone pediatric
Route
ORAL
Dosage forms
• Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk ( 5.1 ) • Prader-Willi Syndrome in Children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatment Discontinue treatment if these signs occur ( 5.2 ) • Neoplasm: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm in childhood cancer survivors treated with somatropin in particular meningiomas in patients treated with radiation to the head for their first neoplasm ( 5.3 ) • Impaired Glucose Tolerance and Diabetes Mellitus: May be unmasked Periodically monitor glucose levels in all patients. Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment ( 5.4 ) • Intracranial Hypertension: Exclude preexisting papilledema. May develop and is usually reversible after discontinuation or dose reduction ( 5.5 ) • Hypersensitivity: Serious hypersensitivity reactions may occur. In the event of an allergic reaction, seek prompt medical attention ( 5.6 ) • Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome – especially in adults): May occur frequently. Reduce dose as necessary ( 5.7 ) • Hypoadrenalism: Monitor patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism ( 5.8 ) • Hypothyroidism: May first become evident or worsen. Monitor thyroid function periodically ( 5.9 ) • Slipped Capital Femoral Epiphysis: May develop. Evaluate children with the onset of a limp or hip/knee pain ( 5.10 ) • Progression of Preexisting Scoliosis: Monitor any child with scoliosis for progression of the curve ( 5.11 ) • Pancreatitis: Consider pancreatitis in patients with persistent severe abdominal pain ( 5.15 )
Manufacturer
Pfizer Laboratories Div Pfizer Inc

Approved uses

GENOTROPIN is a recombinant human growth hormone indicated for: • Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi syndrome, Small for Gestational Age, Turner syndrome, and Idiopathic Short Stature ( 1.1 ) • Adult: Treatment of adults with either adult onset or childhood onset GHD ( 1.2 )

How it works

In vitro, preclinical, and clinical tests have demonstrated that GENOTROPIN lyophilized powder is therapeutically equivalent to human growth hormone of pituitary origin and achieves similar pharmacokinetic profiles in normal adults. In pediatric patients who have growth hormone deficiency (GHD), have Prader-Willi syndrome (PWS), were born small for gestational age (SGA), have Turner syndrome (TS), or have Idiopathic short stature (ISS), treatment with GENOTROPIN stimulates linear growth. In patients with GHD or PWS, treatment with GENOTROPIN also normalizes concentrations of IGF-I (Insulin-like Growth Factor-I/Somatomedin C). In adults with GHD, treatment with GENOTROPIN results in reduced fat mass, increased lean body mass, metabolic alterations that include beneficial changes in lipid metabolism, and normalization of IGF-I concentrations. In addition, the following actions have been demonstrated for GENOTROPIN and/or somatropin.

Warnings and precautions

WARNINGS: Do not use if you have ever had an allergic reaction to this product or any of its ingredients. Ask a doctor before use if you have been diagnosed with a condition known to weaken immunity such as HIV, the virus that causes AIDS. Stop use and ask a doctor if symptoms persist for more than 7 days, worsen, or if new symptoms occur. Keep out of reach of children. In case of overdose, get medical help or call a Poison Control Center right away. If pregnant or breast-feeding, ask a health professional before use. Do not use if TAMPER EVIDENT seal around neck of bottle is missing or broken. Store at room temperature.

Contraindications

Acute Critical Illness ( 4 ) • Children with Prader-Willi syndrome who are severely obese or have severe respiratory impairment – reports of sudden death ( 4 ) • Active Malignancy ( 4 ) • Hypersensitivity to somatropin or excipients ( 4 ) • Active Proliferative or Severe Non-Proliferative Diabetic Retinopathy ( 4 ) • Children with closed epiphyses ( 4 )

Common side effects

Subject (3%); Subjects (30%); Patients (0.4%)

Dosage and administration

The weekly dose should be divided into 6 or 7 subcutaneous injections. GENOTROPIN must not be injected intravenously. Therapy with GENOTROPIN should be supervised by a physician who is experienced in the diagnosis and management of pediatric patients with growth failure associated with growth hormone deficiency (GHD), Prader-Willi syndrome (PWS), Turner syndrome (TS), those who were born small for gestational age (SGA) or Idiopathic Short Stature (ISS), and adult patients with either childhood onset or adult onset GHD.

Drug interactions

Inhibition of 11ß-Hydroxysteroid Dehydrogenase Type 1: May require the initiation of glucocorticoid replacement therapy. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance doses ( 7.1 , 7.2 ). • Glucocorticoid Replacement: Should be carefully adjusted ( 7.2 ) • Cytochrome P450-Metabolized Drugs: Monitor carefully if used with somatropin ( 7.3 ) • Oral Estrogen: Larger doses of somatropin may be required in women ( 7.4 ) • Insulin and/or Oral/Injectable Hypoglycemic Agents: May require adjustment ( 7.5 )

Common questions

What is Genotropin approved to treat?

According to its FDA label, Genotropin (growth hormone pediatric) is approved for: GENOTROPIN is a recombinant human growth hormone indicated for: • Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi syndrome, Small for Gestational Age, Turner syndrome, and Idiopathic Short Stature ( 1.1 ) • Adult: Treatmen… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Genotropin?

Genotropin (growth hormone pediatric) belongs to the Growth Hormone class of medications.

What form does Genotropin come in?

The FDA label lists Genotropin (growth hormone pediatric) as: Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk ( 5.1 ) • Prader-Willi Syndrome in Children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatment Discontinue treatment if these signs occur ( 5.2 ) • Neoplasm: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm in childhood cancer survivors treated with somatropin in particular meningiomas in patients treated with radiation to the head for their first neoplasm ( 5.3 ) • Impaired Glucose Tolerance and Diabetes Mellitus: May be unmasked Periodically monitor glucose levels in all patients. Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment ( 5.4 ) • Intracranial Hypertension: Exclude preexisting papilledema. May develop and is usually reversible after discontinuation or dose reduction ( 5.5 ) • Hypersensitivity: Serious hypersensitivity reactions may occur. In the event of an allergic reaction, seek prompt medical attention ( 5.6 ) • Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome – especially in adults): May occur frequently. Reduce dose as necessary ( 5.7 ) • Hypoadrenalism: Monitor patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism ( 5.8 ) • Hypothyroidism: May first become evident or worsen. Monitor thyroid function periodically ( 5.9 ) • Slipped Capital Femoral Epiphysis: May develop. Evaluate children with the onset of a limp or hip/knee pain ( 5.10 ) • Progression of Preexisting Scoliosis: Monitor any child with scoliosis for progression of the curve ( 5.11 ) • Pancreatitis: Consider pancreatitis in patients with persistent severe abdominal pain ( 5.15 ); oral route. Available strengths and packaging vary by manufacturer.

Does Genotropin have a Boxed Warning?

Our ingest of the FDA label for Genotropin (growth hormone pediatric) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Genotropin cost?

Public CMS NADAC pricing for Genotropin (growth hormone pediatric) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Genotropin currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Genotropin (growth hormone pediatric) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Genotropin approved by the FDA?

The FDA record lists the approval date for Genotropin (growth hormone pediatric) as 1995-08-24.

Who makes Genotropin?

The FDA label lists Pfizer Laboratories Div Pfizer Inc as a labeler/manufacturer of Genotropin (growth hormone pediatric). Multiple firms may market generics of the same molecule.

How should Genotropin be stored?

The FDA label states: "GENOTROPIN (somatropin) for injection is a white, lyophilized powder in a single-patient-use or single-dose, two-chamber cartridge intended for subcutaneous injection after reconstitution. The front chamber contains soma…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…